Generic selectors
Exact matches only
Search in title
Search in content
Post Type Selectors

MRUS – Merus N.V

Float Short %

6.88

Margin Of Safety %

Put/Call OI Ratio

0.63

EPS Next Q Diff

0.97

EPS Last/This Y

-2.65

EPS This/Next Y

1.44

Price

67.54

Target Price

92.93

Analyst Recom

1

Performance Q

62.24

Relative Volume

0.66

Beta

1.2

Ticker: MRUS




21 items of 1

DateSymbolLastP/C OIP/C VolTotal OI
2025-07-25MRUS66.940.625.4113182
2025-07-28MRUS65.660.680.3813716
2025-07-29MRUS65.840.681.1813724
2025-07-30MRUS66.270.682.5713770
2025-07-31MRUS66.240.690.7913792
2025-08-01MRUS65.50.693.8613843
2025-08-04MRUS66.960.690.0613859
2025-08-05MRUS67.470.670.6014196
2025-08-06MRUS65.60.670.0814253
2025-08-07MRUS63.40.630.1314803
2025-08-08MRUS63.970.6311.8314844
2025-08-11MRUS64.60.740.5016134
2025-08-12MRUS63.750.730.0216148
2025-08-13MRUS67.190.730.6416241
2025-08-14MRUS66.940.713.8823587
2025-08-15MRUS67.270.720.1723711
2025-08-18MRUS65.960.630.2920660
2025-08-19MRUS63.350.630.3320781
2025-08-20MRUS64.450.630.3120822
2025-08-21MRUS66.670.630.6620838
2025-08-22MRUS67.460.630.0320860
DateSymbolLastP/C OIP/C VolTotal OI
21 items Current Page1 of 1




21 items of 1

DateTickerPriceCurrent Quarter Growth EstimateEBIT EstimationAverage EPS Estimate Current Year
2025-07-25MRUS66.82-42.5-67.7-4.71
2025-07-28MRUS65.93-42.5-55.5-4.71
2025-07-29MRUS65.92-42.5-62.8-4.71
2025-07-30MRUS66.16-42.5-62.7-4.71
2025-07-31MRUS66.24-42.5-61.3-4.71
2025-08-01MRUS65.56-42.5-56.8-4.71
2025-08-04MRUS66.93-42.5-69.6-4.71
2025-08-05MRUS67.45-42.5-64.0-4.71
2025-08-06MRUS65.57-42.5-49.8-4.71
2025-08-07MRUS63.3924.82.0-4.71
2025-08-08MRUS64.0024.8-15.9-5.19
2025-08-11MRUS64.599.4-15.7-5.92
2025-08-12MRUS63.789.4-6.3-5.92
2025-08-13MRUS67.098.8-33.9-6.00
2025-08-14MRUS66.968.8-11.0-6.00
2025-08-15MRUS67.258.8-13.7-6.00
2025-08-18MRUS65.968.8-3.8-6.00
2025-08-19MRUS63.658.83.2-6.00
2025-08-20MRUS64.438.8-17.1-6.00
2025-08-21MRUS66.678.8-26.5-6.00
2025-08-22MRUS67.548.8-17.5-6.00
DateTickerPriceCurrent Quarter Growth EstimateEBIT EstimationAverage EPS Estimate Current Year
21 items Current Page1 of 1




21 items of 1

DateTickerInsider TransactionsInstitutional TransactionsFloat Short
2025-07-25MRUS-1.05-1.486.85
2025-07-28MRUS-1.05-1.516.85
2025-07-29MRUS-1.05-1.516.85
2025-07-30MRUS-1.05-1.516.85
2025-07-31MRUS-1.05-1.516.85
2025-08-01MRUS-1.05-1.516.85
2025-08-04MRUS-1.05-0.816.85
2025-08-05MRUS-1.05-0.816.85
2025-08-06MRUS-1.05-0.816.85
2025-08-07MRUS-1.05-0.816.85
2025-08-08MRUS-1.03-0.816.75
2025-08-11MRUS-1.03-0.806.75
2025-08-12MRUS-1.03-0.806.97
2025-08-13MRUS-1.03-0.806.97
2025-08-14MRUS-1.03-0.806.97
2025-08-15MRUS-1.03-0.806.97
2025-08-18MRUS-1.03-0.066.96
2025-08-19MRUS-1.04-0.066.96
2025-08-20MRUS-1.04-0.066.96
2025-08-21MRUS-1.04-0.066.96
2025-08-22MRUS-1.04-0.066.88
DateTickerInsider TransactionsInstitutional TransactionsFloat Short
21 items Current Page1 of 1

Last Quarter Act. EPS

-2.23

Avg. EPS Est. Current Quarter

-1.33

Avg. EPS Est. Next Quarter

-1.26

Insider Transactions

-1.04

Institutional Transactions

-0.06

Beta

1.2

Average Sales Estimate Current Quarter

8

Average Sales Estimate Next Quarter

9

Fair Value

Quality Score

20

Growth Score

34

Sentiment Score

77

Actual DrawDown %

0.1

Max Drawdown 5-Year %

-60.4

Target Price

92.93

P/E

Forward P/E

PEG

P/S

90.78

P/B

6.06

P/Free Cash Flow

EPS

-5.54

Average EPS Est. Cur. Y​

-6

EPS Next Y. (Est.)

-4.56

Target Price Estimates Raised

1

Target Price Estimates Lowered

Profit Margin

-685.64

Relative Volume

0.66

Return on Equity vs Sector %

-70.5

Return on Equity vs Industry %

-57.6

EPS 1 7Days Diff

-1.3

EPS 1 30Days Diff

-1.29

EBIT Estimation

-17.5
Merus N.V.
Sector: Healthcare
Industry: Biotechnology
Employees: 260
Merus N.V., a clinical-stage immuno-oncology company, engages in the development of antibody therapeutics in the Netherlands. Its bispecific antibody candidate pipeline includes BIZENGRI for the treatment of patients with pancreatic adenocarcinoma or non-small cell lung cancer (NSCLC) and non Neuregulin 1. The company is also developing MCLA-158 for the treatment of solid tumors; MCLA-129 for the treatment of patients with lungs and other solid tumors; ONO-4685 to treat relapsed/refractory T cell lymphoma; and INCA33890 for advanced solid tumors. In addition, it has collaboration agreement with Eli Lilly and Company, Ono Pharmaceutical Co., Ltd., and Betta Pharmaceuticals Co. Ltd. The company was incorporated in 2003 and is headquartered in Utrecht, the Netherlands.
stock quote shares MRUS – Merus N.V Stock Price stock today
news today MRUS – Merus N.V stock forecast ,stock prediction 2023 2024 2025
marketwatch MRUS – Merus N.V yahoo finance google finance
stock history MRUS – Merus N.V invest stock market
stock prices MRUS premarket after hours
ticker MRUS fair value insiders trading